#China #Guangzhou #AMD #QA102 #MingMed

Positive Phase II Results for QA102

MingMed Biotechnology Co., Ltd., a pioneering biomedical company, recently presented the promising outcomes from its Phase II clinical trial of its oral treatment candidate, QA102, aimed at addressing intermediate dry age-related macular degeneration (AMD). This significant announcement was made during the annual Association for Research in Vision and Ophthalmology (ARVO) meeting held in Denver, Colorado, in 2026.

Understanding Intermediate Dry AMD

Intermediate dry AMD is a progressive retinal condition characterized by the accumulation of large drusen and pigmentary changes in the eye. This stage of AMD is particularly concerning as it poses a considerable risk for progression to more serious forms of the disease, which can lead to irreversible blindness. The growing prevalence of AMD in the older adult population is alarming, with nearly 7% of individuals aged 65 and over in the United States affected by this condition.

Study Overview

The trial, named QA102-CS201, was a double-masked, randomized, placebo-controlled study that involved 150 participants with intermediate atrophic AMD. The subjects were assigned to receive either oral QA102 in doses of 200 mg or 400 mg, or a placebo, twice daily (BID) for a period of up to 15 months. After 12 months of treatment, notable results were observed. The mean change in drusen volume showed a substantial reduction of 59.2% in those receiving the 400 mg dose compared to the placebo group. Additionally, while the primary efficacy endpoint did not achieve statistical significance, a remarkable reduction in the growth rate of drusen volume by 118.2% was noted (p=0.017), along with a 42.7% decrease in the growth rate of the square-root transformed geographic atrophy (GA) area compared to those on placebo (p=0.026).

Expert Commentary

Dr. Scott Whitcup, an authority in ophthalmic drug development, emphasized the importance of addressing intermediate AMD, stating, "This stage represents the most common form of the disease, yet there is a critical lack of effective therapies to manage or halt its progression. The data from the Phase II study of QA102 is extremely promising for the millions suffering from either intermediate or advanced stages of dry AMD."

Supporting this sentiment, Dr. Sunil Patel, MD, PhD, who served as a principal investigator for the study, expressed his optimism about the results.

Future Prospects

Fred Ouyang, PhD and Chief Technology Officer of MingMed Biotechnology, expressed his excitement about presenting these compelling Phase II findings to a global audience within the ophthalmology community at ARVO. "QA102 represents a pioneering oral treatment for atrophic AMD," he stated, adding that it is the first candidate to show potential efficacy in addressing intermediate dry AMD. The enthusiasm surrounding QA102's future is palpable, as the company prepares to move forward with subsequent phases of clinical development.

About MingMed Biotech

MingMed Biotechnology's commitment to innovation extends through its subsidiary, Smilebiotek Zhuhai Limited, which is focused on developing cutting-edge ophthalmology products. Their pipeline includes two noteworthy candidates: QA102, a new chemical entity tailored for AMD, and QA108, which draws on traditional Chinese medicine.

MingMed Biotechnology's advancements in AMD treatments signal a critical step towards addressing a pressing medical need, reinforcing their dedication to improving the lives of millions affected by this sight-threatening condition.